In today’s world, the average adult between the ages of 65 and 69 takes almost 14 prescriptions per year, and those aged 80-84 take 18 prescriptions. With the safety information for each medication constantly changing, it can be difficult for consumers to be informed about their medications.
This is a Request for Proposal to lease the Good Manufacturing Practices (GMP) facility located at the Institute for Bioscience and Biotechnology Research (IBBR), on the University System of Maryland’s Shady Grove campus at 9600 Gudelsky Drive, Rockville, MD 20850.
IBBR is a University System of Maryland joint research enterprise between the University of Maryland College Park, The University of Maryland Baltimore and the National Institute of Standards and Technology. IBBR’s Vision and Mission are as follows:
Johns Hopkins University President Ronald Daniels has seen plenty of innovation at the world-renowned research institution he leads. In opening a second incubator in East Baltimore, university officials believe they can get another benefit from the innovation.
“It’s happened before at Hopkins and it’ll happen again,” Daniels said of inventions that come out of the university. “But this time, we’re going to make some money on it.”
Sucampo Pharmaceuticals, a global biopharmaceutical company, announced that Sucampo and R-Tech Ueno, Ltd. (RTU), have entered into a stipulation and licence agreement with Par Pharmaceutical, Inc. (Par). The agreement states that in limited circumstances, Sucampo or RTU would grant Par a licence for a generic version of the RESCULA (unoprostone isopropyl ophthalmic solution) 0.15 per cent product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Par had previously submitted an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market, sell, and use a generic version of RESCULA.
Maryland could establish a $5 million fund to put toward tax credits for individuals and firms who invest in startup companies.
Startup and investor advocates, including the Greater Baltimore Committee, have said they will push for the state to create a new tax credit specifically for angel investors who give money to companies at their earliest stages, when they often struggle to bring in needed cash. A bill introduced by Baltimore City Democrat Sen. Catherine Pugh earlier this month details how the tax credit would work and who could qualify as an investor and startup recipient.
Four University System of Maryland schools rank among the top 100 public universities in the country, according to a new statistical analysis by The Business Journals.
University of Maryland, College Park, scored highest among Maryland’s public universities, coming in at No. 8 out of 484 schools nationwide. St. Mary’s College of Maryland; University of Maryland, Baltimore County; and Towson University also ranked in the top 100. Salisbury University ranked 107th.
April 27-29, 2015 – Boston, MA
Partners HealthCare is proud to announce the 2015 World Medical Innovation Forum, an annual gathering in Boston of more than 1,000 top innovation decision makers. The inaugural event will focus on neurosciences and be held on April 27-29, 2015. The goals of this three-day event are to identify today’s leading neuroscience innovations, address unmet needs, and discuss the critical issues affecting technology development and implementation in this new, evolving era of value-based care.
While regulation of diagnostic tests by the Food and Drug Administration (FDA) may not directly impact the biobanking industry, it does have an impact on the development of new therapies, particularly personalized medicine, and all of us have a stake in the future of personalized medicine.
National Institutes of Health director Francis Collins kicked off a two-day meeting in Bethesda, MD, this morning to discuss how to turn President Obama’s call for a national health research database into reality. The database, which NIH officials are calling the National Research Cohort, is one of two main thrusts of the administration’s precision medicine initiative.
Fourteen years ago, during the darkest moments of the “stem-cell wars” pitting American scientists against the White House of George W. Bush, one group of advocates could be counted on to urge research using cells from human embryos: parents of children with type 1 diabetes. Motivated by scientists who told them these cells would lead to amazing cures, they spent millions on TV ads, lobbying, and countless phone calls to Congress.
